Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
MDGL similar filings
- 30 Sep 16 Changes in Registrant's Certifying Accountant
- 2 Sep 16 Unaudited Interim Condensed Financial Statements
- 11 Aug 16 Richard S. Levy, M. D., Appointed to Madrigal Board of Directors
- 22 Jul 16 Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading Cardiovascular-Metabolic Diseases and NASH Company
- 8 Jun 16 Other Events
- 3 Jun 16 Other Events
- 2 Jun 16 Synta Pharmaceuticals to Present at Upcoming Investor Conferences in June
Filing view
External links
Exhibit 16.1
July 22, 2016
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Ladies and Gentlemen:
We have read Item 4.01 of Form 8-K dated July 22, 2016, of Madrigal Pharmaceuticals, Inc. (formerly known as “Synta Pharmaceuticals Corp.”) and are in agreement with the statements contained in the second, third and fourth paragraphs therein. We have no basis to agree or disagree with other statements of the registrant contained therein.
/s/ Ernst & Young LLP